Purchase Summary

In order to access content on the FENIX Marketplace, you must have an account. You will also have access to FENIX Free updates.

The price for access is $599.00.

Account Information Already have an account? Log in here

LEAVE THIS BLANK

Payment Information We accept all major credit cards

By selecting this, I agree to receive emails from fenix.group.

You will be redirected to view the full article after purchasing. You will receive your account and payment information in a confirmation email, and can be viewed at any time in your Account.
RETURN TO HOME
$599
Dual/triple agonist, Topics

Lilly Dual-Agonist Shows Impressive A1C and Weight Control, High Rate of GI AEs

Here is a brief preview of this blast: Lilly presented results from a Ph2b study evaluating its GIP/GLP-1 dual-agonist (LY3298176) vs. 1.5mg Trulicity, both dosed QW. The results were also published in The Lancet. The trial demonstrated at 26 weeks up to -2.4% reductions in A1C and -11.3 kg weight loss on the highest dose of the LY dual-agonist. Of note, Lilly disclosed plans to initiate Ph3 for LY3298176 “no later than early 2019” with trial completion in 2021. The T2DM Ph3 program will be called “SURPASS,” which seems like it could be a subtle dig at Novo’s injectable semaglutide Ph3 program called SUSTAIN, since Lilly will attempt to surpass semaglutide with its dual-agonist. Additionally, Lilly said it is planning to evaluate the GIP/GLP-1RA in obesity and “…other conditions” (likely NASH). Below, FENIX provides an overview of the LY Ph2b results and their potential impact to Novo Nordisk and Sanofi.

About The Author

Matthew Maryniak

|
President of Fenix Group International
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.